Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients

Palisade Bio Inc. (NASDAQ:PALI) is one of the best growth stocks to buy right now. On February 23, Palisade Bio presented translational data from its Phase 1b study of PALI-2108. The findings highlight that this once-daily oral prodrug, designed for targeted delivery to the terminal ileum and colon, achieved localized target engagement and clinical response within 7 days in patients with moderate-to-severe ulcerative colitis.

The data showed a 100% clinical response rate and a 40% clinical remission rate based on modified Mayo Scores, supported by a safety profile across 89 total subjects with no serious adverse events or treatment discontinuations. Mechanism-of-action data derived from colon tissue RNA sequencing confirmed that PALI-2108 successfully suppresses inflammatory and fibrotic gene programs. The results were accompanied by reduced mucosal PDE4B expression, increased tissue cAMP levels, and decreased inflammatory cell signatures. These pharmacologic effects were concentrated in the colonic tissue, while peripheral immune profiles remained largely unchanged, validating the drug’s localized activity.

PALI-2108 uses local bacterial bioactivation to ensure the PDE4 inhibitor remains inactive until it reaches the lower intestine. This targeted approach is engineered to prevent upper gut absorption and minimize peak plasma levels, thereby reducing common systemic side effects such as nausea, headache, and diarrhea. Palisade Bio Inc. (NASDAQ:PALI) believes the convergence of clinical response, tissue pharmacodynamics, and gene expression modulation de-risks the program as PALI-2108 moves into later-stage clinical development.

Palisade Bio Inc. (NASDAQ:PALI) operates as a clinical-stage biopharmaceutical company that develops and advances novel therapeutics for autoimmune, inflammatory, and fibrotic diseases.

While we acknowledge the risk and potential of PALI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PALI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years

Disclosure: None. Follow Insider Monkey on Google News.